<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281189</url>
  </required_header>
  <id_info>
    <org_study_id>223AS302</org_study_id>
    <secondary_id>EUDRA CT NO: 2010-022818-19</secondary_id>
    <nct_id>NCT01281189</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Dexpramipexole in ALS</brief_title>
  <acronym>EMPOWER</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knopp Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Knopp Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe&#xD;
      and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive, degenerative disease of motor&#xD;
      neurons in the brain and spinal cord that leads to muscle atrophy and spasticity in limb and&#xD;
      bulbar muscles resulting in weakness and loss of ambulation, oropharyngeal dysfunction,&#xD;
      weight loss, and ultimately respiratory failure. The purpose of this study is to determine&#xD;
      whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Assessment of Function and Survival (CAFS) at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>The Composite Assessment of Function and Survival (CAFS) is a between-group comparison of a single ranked clinical outcome based on (1) the change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) score and (2) time to death. Each subject is ranked according to time-to-death (earlier deaths ranked lower than later deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than less worsening or an improvement in ALSFRS-R). The ranked scores range from 001 to 941 (the number of subjects in the Efficacy Population) with larger rank score numbers associated with a better outcome. The ranks were analyzed using an ANCOVA model, which includes treatment as a fixed effect and adjusts for baseline ALSFRS-R score, duration of symptoms, site of onset, and use of riluzole. The least square mean rank score is presented for each treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death up to 12 Months (CAFs Individual Component)</measure>
    <time_frame>12 months</time_frame>
    <description>The longest duration of follow-up for this time to the death analysis was 12 months. In the study, subjects were followed for 12-18 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in ALSFRS-R at 12 Months (CAFs Individual Component)</measure>
    <time_frame>12 months</time_frame>
    <description>The ALSFRS-R (ALS functional rating scale with respiratory component) is a validated scale which measures 4 functional domains, comprising respiratory function, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48, with higher scores representing better function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death or Respiratory Insufficiency (DRI) up to Month 18</measure>
    <time_frame>18 months</time_frame>
    <description>Time to Death or Respiratory Insufficiency (DRI) is defined as receipt of a tracheostomy or the use of non-invasive ventilation (NIV) for ≥22 hours per day for at least 10 consecutive days. If NIV is used to meet the criteria for respiratory insufficiency, no measured slow vital capacity (SVC) at any subsequent assessment may be &gt;50%. Time to DRI is calculated from the date of the first dose to the first date of one of the following events: death, tracheostomy, or the 10th day of consecutive NIV with no measured SVC &gt;50% at any subsequent assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death up to 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Estimated time to death up to 18 months. This includes deaths reported greater than 30 days following discontinuation from the study (the time period for reporting all-cause mortality), regardless of subject disposition, up to 18 months from first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≤50% Predicted Upright Slow Vital Capacity (SVC) or Died up to 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>The date of reaching ≤50% of predicted upright slow vital capacity (SVC) is defined as the date of the first visit at which a predicted upright SVC is ≤50% and continues to remain ≤50% at the subsequent visit except for the last available observation. The time to reach ≤50% of predicted upright SVC is defined as the duration between the date of reaching ≤50% of predicted upright SVC and the date of the first dose of study medication. If the subject is alive and does not reach ≤50% of predicted upright SVC, the time to reach ≤50% of predicted upright SVC will be censored and equal to the number of days from the first dose of study medication until the visit date when the subject's last available SVC assessment is performed. The earliest time (Reaching ≤50% Predicted Upright SVC or death) is used in analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">942</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dexpramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole</intervention_name>
    <description>Oral tablet 150mg twice daily for up to 18 months.</description>
    <arm_group_label>Dexpramipexole</arm_group_label>
    <other_name>KNS-760704</other_name>
    <other_name>BIIB050</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet twice daily for up to 18 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 80 years old, inclusive, on Day 1.&#xD;
&#xD;
          -  Diagnosis of sporadic or familial ALS.&#xD;
&#xD;
          -  Onset of first ALS symptoms within 24 months prior to Day 1.&#xD;
&#xD;
          -  World Federation of Neurology El Escorial criteria are met for a possible,&#xD;
             laboratory-supported probable, probable, or definite ALS diagnosis.&#xD;
&#xD;
          -  Upright slow vital capacity (SVC) of 65% or more at screening.&#xD;
&#xD;
          -  Patients taking or not taking Riluzole are eligible for this study: if a patient has&#xD;
             never taken Riluzole, he or she is eligible; if a patient is currently taking&#xD;
             Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient&#xD;
             has discontinued Riluzole, he or she must have stopped taking it for at least 30 days.&#xD;
&#xD;
          -  Must be able to swallow tablets at the time of study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other medically significant illness.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values.&#xD;
&#xD;
          -  Pregnant women or women breastfeeding.&#xD;
&#xD;
          -  Prior exposure to dexpramipexole.&#xD;
&#xD;
          -  Currently taking pramipexole or other dopamine agonists.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Neurology of the Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute - St. Joseph's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco - Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Medical Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Health Care</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Foundation of the State University of New York</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>12201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALS Center at Penn</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Health Care Bethlehem</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Calgary / Foothills MC</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mcgill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook and Women's College and Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de l'Archet 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bergmannsheil Gmbh</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm, RKU</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walton Centre for Neurology &amp; Neurosurgery</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University Hospital - Clinical Ageing Research Unit</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Institute for Transnational Neuroscience</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <results_first_submitted>December 4, 2020</results_first_submitted>
  <results_first_submitted_qc>May 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2021</results_first_posted>
  <disposition_first_submitted>November 24, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 24, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2014</disposition_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Motor Neurone Disease</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 942 participants (468 received placebo and 474 received dexpramipexole) recruited from 81 investigational sites in 11 countries worldwide. One additional participant was randomized in error and was not dosed. This subject was assigned to the placebo arm, but was removed from the intent-to-treat population as a result of the unintentional randomization performed in error by the site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo: Oral tablet twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Dexpramipexole</title>
          <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="331"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population is defined as subjects who were randomized and received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo: Oral tablet twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Dexpramipexole</title>
          <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="468"/>
            <count group_id="B2" value="474"/>
            <count group_id="B3" value="942"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age (yrs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;50</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50-65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="477"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="439"/>
                    <measurement group_id="B2" value="450"/>
                    <measurement group_id="B3" value="889"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Not all subject in the safety population had valid weights collected at Baseline</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="465"/>
                    <count group_id="B2" value="471"/>
                    <count group_id="B3" value="936"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.76" spread="16.008"/>
                    <measurement group_id="B2" value="77.21" spread="15.027"/>
                    <measurement group_id="B3" value="77.48" spread="15.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.0" spread="10.22"/>
                    <measurement group_id="B2" value="172.0" spread="9.30"/>
                    <measurement group_id="B3" value="172.0" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <population>Not all subject in the safety population had valid weights collected at Baseline, therefore BMI could not be calculated.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="465"/>
                    <count group_id="B2" value="471"/>
                    <count group_id="B3" value="936"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.15" spread="4.330"/>
                    <measurement group_id="B2" value="26.00" spread="4.239"/>
                    <measurement group_id="B3" value="26.08" spread="4.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALS family history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="882"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since ALS symptom onset</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.53" spread="5.411"/>
                    <measurement group_id="B2" value="14.92" spread="5.251"/>
                    <measurement group_id="B3" value="15.22" spread="5.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of onset</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Bulbar</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since ALS diagnosis</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.62" spread="5.015"/>
                    <measurement group_id="B2" value="7.22" spread="4.718"/>
                    <measurement group_id="B3" value="7.42" spread="4.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>El Escorial Criteria for ALS</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Possible</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Probable laboratory supported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Probable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Definite</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant use of riluzole</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="708"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline ALSFRS-R total scores</title>
          <description>Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). This validated scale stratifies severity of amyotrophic lateral sclerosis (ALS). The ALSFRS-R consists of 12 items answered across 4 functional domains (bulbar, gross motor, fine motor and respiratory) in which each item is scored between 4 and 0, for a maximum score of 48. A decline in ALSFRS-R indicates a loss of physical function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.9" spread="5.65"/>
                    <measurement group_id="B2" value="38.4" spread="5.24"/>
                    <measurement group_id="B3" value="38.2" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline predicted upright slow vital capacity (%)</title>
          <description>slow vital capacity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;65%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>65-75%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;75%</title>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline predicted upright slow vital capacity (%)</title>
          <description>slow vital capacity</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="468"/>
                    <count group_id="B2" value="474"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.1" spread="17.71"/>
                    <measurement group_id="B2" value="89.0" spread="17.57"/>
                    <measurement group_id="B3" value="89.1" spread="17.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Assessment of Function and Survival (CAFS) at 12 Months</title>
        <description>The Composite Assessment of Function and Survival (CAFS) is a between-group comparison of a single ranked clinical outcome based on (1) the change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) score and (2) time to death. Each subject is ranked according to time-to-death (earlier deaths ranked lower than later deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than less worsening or an improvement in ALSFRS-R). The ranked scores range from 001 to 941 (the number of subjects in the Efficacy Population) with larger rank score numbers associated with a better outcome. The ranks were analyzed using an ANCOVA model, which includes treatment as a fixed effect and adjusts for baseline ALSFRS-R score, duration of symptoms, site of onset, and use of riluzole. The least square mean rank score is presented for each treatment group.</description>
        <time_frame>12 months</time_frame>
        <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo: Oral tablet twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Dexpramipexole</title>
            <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Assessment of Function and Survival (CAFS) at 12 Months</title>
          <description>The Composite Assessment of Function and Survival (CAFS) is a between-group comparison of a single ranked clinical outcome based on (1) the change from baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) score and (2) time to death. Each subject is ranked according to time-to-death (earlier deaths ranked lower than later deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than less worsening or an improvement in ALSFRS-R). The ranked scores range from 001 to 941 (the number of subjects in the Efficacy Population) with larger rank score numbers associated with a better outcome. The ranks were analyzed using an ANCOVA model, which includes treatment as a fixed effect and adjusts for baseline ALSFRS-R score, duration of symptoms, site of onset, and use of riluzole. The least square mean rank score is presented for each treatment group.</description>
          <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.84" lower_limit="412.807" upper_limit="464.878"/>
                    <measurement group_id="O2" value="441.76" lower_limit="415.426" upper_limit="468.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8568</p_value>
            <method>ANCOVA</method>
            <method_desc>Includes treatment as a fixed effect and adjusts for baseline ALSFRS-R total score, duration from sx onset, site of onset, and use of riluzole.</method_desc>
            <param_type>LS Mean Difference (Final Values)</param_type>
            <param_value>2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.751</ci_lower_limit>
            <ci_upper_limit>34.576</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death up to 12 Months (CAFs Individual Component)</title>
        <description>The longest duration of follow-up for this time to the death analysis was 12 months. In the study, subjects were followed for 12-18 months.</description>
        <time_frame>12 months</time_frame>
        <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo: Oral tablet twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Dexpramipexole</title>
            <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Death up to 12 Months (CAFs Individual Component)</title>
          <description>The longest duration of follow-up for this time to the death analysis was 12 months. In the study, subjects were followed for 12-18 months.</description>
          <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8375</p_value>
            <method>Cox Proportional Hazards model</method>
            <method_desc>Adjusted for baseline ALSFRS-R total score, duration from symptom onset to the first dose of study treatment, site of onset, and use of riluzole.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>1.427</ci_upper_limit>
            <other_analysis_desc>Hazard Ratio (HR) (Dex/PBO)</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in ALSFRS-R at 12 Months (CAFs Individual Component)</title>
        <description>The ALSFRS-R (ALS functional rating scale with respiratory component) is a validated scale which measures 4 functional domains, comprising respiratory function, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48, with higher scores representing better function.</description>
        <time_frame>12 months</time_frame>
        <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects will be analyzed in the treatment group to which they are randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo: Oral tablet twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Dexpramipexole</title>
            <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ALSFRS-R at 12 Months (CAFs Individual Component)</title>
          <description>The ALSFRS-R (ALS functional rating scale with respiratory component) is a validated scale which measures 4 functional domains, comprising respiratory function, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48, with higher scores representing better function.</description>
          <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects will be analyzed in the treatment group to which they are randomized.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.415" lower_limit="-14.275" upper_limit="-12.555"/>
                    <measurement group_id="O2" value="-13.339" lower_limit="-14.199" upper_limit="-12.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9019</p_value>
            <method>mixed-effects repeated-measures model</method>
            <method_desc>Mixed-effects repeated-measures model with treatment, visit, treatment-by visit interaction, baseline ALSFRS-R score, baseline-by-visit interaction</method_desc>
            <param_type>LS Mean Difference (Net)</param_type>
            <param_value>0.076</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.128</ci_lower_limit>
            <ci_upper_limit>1.280</ci_upper_limit>
            <estimate_desc>The mixed-effects repeated-measures model also adjusted for the following covariates: duration from symptom onset, site of onset, and use of riluzole.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or Respiratory Insufficiency (DRI) up to Month 18</title>
        <description>Time to Death or Respiratory Insufficiency (DRI) is defined as receipt of a tracheostomy or the use of non-invasive ventilation (NIV) for ≥22 hours per day for at least 10 consecutive days. If NIV is used to meet the criteria for respiratory insufficiency, no measured slow vital capacity (SVC) at any subsequent assessment may be &gt;50%. Time to DRI is calculated from the date of the first dose to the first date of one of the following events: death, tracheostomy, or the 10th day of consecutive NIV with no measured SVC &gt;50% at any subsequent assessment.</description>
        <time_frame>18 months</time_frame>
        <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo: Oral tablet twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Dexpramipexole</title>
            <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Respiratory Insufficiency (DRI) up to Month 18</title>
          <description>Time to Death or Respiratory Insufficiency (DRI) is defined as receipt of a tracheostomy or the use of non-invasive ventilation (NIV) for ≥22 hours per day for at least 10 consecutive days. If NIV is used to meet the criteria for respiratory insufficiency, no measured slow vital capacity (SVC) at any subsequent assessment may be &gt;50%. Time to DRI is calculated from the date of the first dose to the first date of one of the following events: death, tracheostomy, or the 10th day of consecutive NIV with no measured SVC &gt;50% at any subsequent assessment.</description>
          <population>The efficacy population is defined as subjects who were randomized and received at least 1 dose of study treatment and who either had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7715</p_value>
            <method>Cox Proportional Hazards model</method>
            <method_desc>Adjusted for baseline ALSFRS-R total score, duration from symptom onset to the first dose of study treatment, site of onset, and use of riluzole</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.801</ci_lower_limit>
            <ci_upper_limit>1.348</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death up to 18 Months</title>
        <description>Estimated time to death up to 18 months. This includes deaths reported greater than 30 days following discontinuation from the study (the time period for reporting all-cause mortality), regardless of subject disposition, up to 18 months from first dose.</description>
        <time_frame>18 months</time_frame>
        <population>Subjects who were randomized, received at least 1 dose of study treatment, had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized. An attempt was made to collect living status for each subject 18 months after randomization, regardless of the subject's disposition in the study (active or discontinued) or primary reasons for discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo: Oral tablet twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Dexpramipexole</title>
            <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Death up to 18 Months</title>
          <description>Estimated time to death up to 18 months. This includes deaths reported greater than 30 days following discontinuation from the study (the time period for reporting all-cause mortality), regardless of subject disposition, up to 18 months from first dose.</description>
          <population>Subjects who were randomized, received at least 1 dose of study treatment, had at least 1 available post-dosing efficacy evaluation (ALSFRS-R) or died during the study period. Subjects were analyzed in the treatment group to which they are randomized. An attempt was made to collect living status for each subject 18 months after randomization, regardless of the subject's disposition in the study (active or discontinued) or primary reasons for discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9033</p_value>
            <method>Cox Proportional Hazards model</method>
            <method_desc>adjusted for baseline ALSFRS-R total score, duration from symptom onset to the first dose of study treatment, site of onset, and use of riluzole</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.745</ci_lower_limit>
            <ci_upper_limit>1.298</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>≤50% Predicted Upright Slow Vital Capacity (SVC) or Died up to 18 Months</title>
        <description>The date of reaching ≤50% of predicted upright slow vital capacity (SVC) is defined as the date of the first visit at which a predicted upright SVC is ≤50% and continues to remain ≤50% at the subsequent visit except for the last available observation. The time to reach ≤50% of predicted upright SVC is defined as the duration between the date of reaching ≤50% of predicted upright SVC and the date of the first dose of study medication. If the subject is alive and does not reach ≤50% of predicted upright SVC, the time to reach ≤50% of predicted upright SVC will be censored and equal to the number of days from the first dose of study medication until the visit date when the subject's last available SVC assessment is performed. The earliest time (Reaching ≤50% Predicted Upright SVC or death) is used in analysis.</description>
        <time_frame>18 months</time_frame>
        <population>The intent-to-treat (ITT) population is defined as subjects who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo: Oral tablet twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Dexpramipexole</title>
            <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>≤50% Predicted Upright Slow Vital Capacity (SVC) or Died up to 18 Months</title>
          <description>The date of reaching ≤50% of predicted upright slow vital capacity (SVC) is defined as the date of the first visit at which a predicted upright SVC is ≤50% and continues to remain ≤50% at the subsequent visit except for the last available observation. The time to reach ≤50% of predicted upright SVC is defined as the duration between the date of reaching ≤50% of predicted upright SVC and the date of the first dose of study medication. If the subject is alive and does not reach ≤50% of predicted upright SVC, the time to reach ≤50% of predicted upright SVC will be censored and equal to the number of days from the first dose of study medication until the visit date when the subject's last available SVC assessment is performed. The earliest time (Reaching ≤50% Predicted Upright SVC or death) is used in analysis.</description>
          <population>The intent-to-treat (ITT) population is defined as subjects who were randomized and received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                    <measurement group_id="O2" value="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7720</p_value>
            <method>Cox Proportional Hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.789</ci_lower_limit>
            <ci_upper_limit>1.192</ci_upper_limit>
            <estimate_desc>Hazard ratio (Dex/PBO)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo: Oral tablet twice daily.</description>
        </group>
        <group group_id="E2">
          <title>Dexpramipexole</title>
          <description>Dexpramipexole: Oral tablet 150 mg twice daily. 300 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DIASTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>STRESS CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>APHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>EUTHANASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DEVICE INSERTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEVICE LEAKAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CYSTITIS ESCHERICHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAS BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RHINOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GAS GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PNEUMONIA KLEBSIELLA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SERRATIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SPLENIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INTENTIONAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SKELETAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURED BASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>TRENCH FOOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>VITAL CAPACITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INVESTIGATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DIAGNOSTIC PROCEDURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>TOTAL LUNG CAPACITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MOBILITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INCLUSION BODY MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NOSE DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CHRONIC LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>METASTATIC BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AMYOTROPHIC LATERAL SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MOTOR NEURONE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASTICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>BULBAR PALSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CEREBELLAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>BREAST HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CHRONIC RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>COUGH DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPERCAPNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPOVENTILATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INCREASED BRONCHIAL SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ORTHOPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>UPPER AIRWAY OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>INCREASED VISCOSITY OF BRONCHIAL SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LARYNGOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>STRIDOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>VOCAL CORD DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>RESPITE CARE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SOCIAL STAY HOSPITALISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>SUPPORTIVE CARE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="447" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="459" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>SALIVARY HYPERSECRETION</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>AMYOTROPHIC LATERAL SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must be consulted</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Regulatory</name_or_title>
      <organization>Knopp Biosciences</organization>
      <phone>4124881776</phone>
      <email>greg@knoppbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

